Molecular Cloning, Expression, and Chromosomal Localization of the Human Earliest Lymphocyte Activation Antigen AIM/CD69, a New Member of the C-Type Animal Lectin Superfamily of Signal-transmitting Receptors

By Manuel López-Cabrera, Ana G. Santis, Elena Fernández-Ruiz, Russ Blacher,* Fred Esch,* Paloma Sánchez-Mateos, and Francisco Sánchez-Madrid

From the Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, 28006 Madrid, Spain; and *Athena Neurosciences, San Francisco, California 94080

Summary
The activation of T lymphocytes, both in vivo and in vitro, induces the expression of CD69. This molecule, which appears to be the earliest inducible cell surface glycoprotein acquired during lymphoid activation, is involved in lymphocyte proliferation and functions as a signal transmitting receptor in lymphocytes, natural killer (NK) cells, and platelets. To determine the structural basis for CD69 function, the cDNA coding for CD69 was isolated by a polymerase chain reaction–based strategy using oligonucleotides deduced from peptide sequences of the purified protein. The isolated cDNA exhibited a single open reading frame of 597 bp coding for CD69, and predicted a 199-amino acid protein of type II membrane topology, with extracellular (COOH-terminal), transmembrane, and intracellular domains. The CD69 clone hybridized to a 1.7-kb mRNA species, which was rapidly induced and degraded after lymphocyte stimulation, consistent with the presence of rapid degradation signals at the 3′ untranslated region. Transient expression of the polypeptide encoded by CD69 cDNA in COS-7 cells demonstrated that it presented properties comparable to native CD69 protein. The CD69 gene was regionally mapped to chromosome 12 p13-p12 by both somatic cell hybrid DNA analysis and fluorescence in situ hybridization coupled with GTG banding (G bands by trypsin using Giemsa). Protein sequence homology search revealed that CD69 is a new member of the Ca2+-dependent (C-type) lectin superfamily of type II transmembrane receptors, which includes the human NKG2, the rat NKR-P1, and the mouse NKR-P1 families of NK cell-specific genes. CD69 also has structural homology with other type II lectin cell surface receptors, such as the T cell antigen Ly49, the low avidity immunoglobulin E receptor (CD23), and the hepatic asialoglycoprotein receptors. The CD69 protein also shares functional characteristics with most members of this superfamily, which act as transmembrane signaling receptors in early phases of cellular activation.

The activation of T lymphocytes by antigens or mitogens initiates a coordinate up- and downregulation of the expression of a wide number of known genes (1). The genes that are induced during the early phase of cell activation are also known as immediate-early genes. To this group belong several protooncogenes, such as c-fos, c-jun, or c-myb, and genes encoding molecules involved in signaling events, including triggering molecules, growth factors, and some cytokine receptors (1, 2).

The CD69 molecule (3), also designated as activation inducer molecule (AIM) (4), early activation antigen (EA-1) (5), Leu-23 (6), or MLR-3 (7) antigens, is a phosphorylated disulfide-linked 27/33-kD homodimeric protein (8). This antigen seems to be the earliest inducible cell surface glycoprotein and is synthesized de novo and expressed upon T lymphocyte activation with a wide variety of stimuli, such as anti-CD3/TCR and anti-CD2 mAbs, activators of protein kinase C, or PHA (4, 5, 9, 10). The expression of CD69 by IL-2-activated NK cells parallels the acquisition of lytic activity by these cells (6). CD69 is undetectable on the plasma membrane of most circulating PBL; however, this molecule is expressed by a large fraction of T cells in the inflammatory infiltrates of several human diseases (11, 12), as well as by a small percentage of resident T and B cells in different normal lymphoid tissues (13). In this context, CD69 expression on thymocytes has been associated with the acquisition of im-
munocompetence during T cell maturation (14, 15). Other cell types, including platelets and epidermal Langerhans cells, also express the CD69 molecule (16, 17).

The CD69 glycoprotein functions as a signal-transmitting receptor in different cells. In T cells, the signals triggered by CD69 antibodies include rise of intracellular calcium concentration, expression of the IL-2Rα subunit (CD25), synthesis of different cytokines, such as IL-2, TNF-α, and IFN-γ, and cell proliferation (4, 9, 18-20). Furthermore, the triggering of T cells through the CD69 activation pathway enhances the binding activity of transcription factor AP-1, which plays a key regulatory role in the initial steps of cell activation (21). Likewise, CD69 also acts as a triggering molecule on NK cells and platelets: CD69 antibodies are capable of inducing target cell lysis by IL-2-activated NK cells (22, 23), and of triggering platelet aggregation, Ca2+ influx, and hydrolysis of arachidonic acid (16). The possible coupling of CD69 with a GTP-binding protein has also been reported (24).

In an attempt to understand the molecular basis for the CD69 functions, the cDNA encoding this protein was cloned and its nucleotide sequence determined. We herewith report that CD69 protein is a type II membrane protein with a C-type animal lectin domain. Comparative protein sequence homology indicates that CD69 is a member of a gene superfamily of type II membrane proteins that includes a wide number of mouse, rat, and human NK cell–specific genes that, like CD69, function as signal-transmitting receptors.

Materials and Methods

mAbs. The different anti-CD69 TP1/8, TP1/55, and FAB/1 mAbs, directed to extracellular antigenic determinants of CD69, have been previously described (8). The CH/2 mAb is specific for an intracellular CD69 epitope (6). Monoclonal Ig (IgG1,K) from the myeloma line P3X63 was included as negative control in some assays.

Purification of CD69 Protein. The anti-CD69 FAB/1 mAb (IgG1,K) (8) was purified from ascites fluids by protein A affinity chromatography and coupled to CNBr-activated Sepharose CB4B (Pharmacia, Uppsala, Sweden) at 2 mg/ml. PBL were obtained from buffy coats by Ficoll-Hypaque (Pharmacia) centrifugation. Activation of PBL was carried out by culturing 2 x 10⁶ cells/ml in the presence of PMA (10 ng/ml) and soluble anti-CD3 SFV-T3b mAb for 24 h (4). Activated PBL (2 x 10⁶ cells/ml) were lysed in an R-buffer containing 20 mM Tris-HCl, pH 8.0, 1% Triton X-100, 5 mM iodoacetamide, 1 mM PMSF, 0.2 mM trypsin inhibitor of aprotinin, and 0.025% NaN₃. After 30 min at 4°C, the lysate was clarified by centrifugation at 1,000 x g for 10 min followed by 50,000 x g for 1 h. Preparative scale immunofinity isolation was performed by passing 50 ml of lysate over sequential glycine-quenched Sepharose CL-4B and anti-CD69 FAB/1-Sepharose CL-4B columns at a flow rate of 1 ml/min. The FAB/1 column was washed with a five-column bed volume of 25 mM Tris-HCl, pH 9.5, 1.5 M NaCl, 0.5% Triton X-100, 1 mM iodoacetamide, 0.5 mM PMSF, and 0.025% NaN₃. The column was then washed with 3 vol of 100 mM ammonium acetate, pH 6.0, 25 mM N-ocetyl-β-glucopyranoside (OG). The CD69 protein was eluted with 3 vol of 100 mM ammonium acetate, pH 2.5, 25 mM OG at a flow rate of 0.3 ml/min. Fractions (1 ml) were collected into tubes containing 5 µl of 1 M ammonium bicarbonate. Homogeneity of immunofinity-purified protein was assessed by SDS-PAGE and silver staining.

Protein Digestion, Peptide Purification, and Sequencing. Approximately 200 pmol (1 ml) of purified protein was dissolved with 200 µl of 1 M Na₂HPO₄ and denatured at 100°C for 5 min. After cooling, N-glycanase enzyme [Genzyme Corp., Cambridge, MA] was added and incubated for 16 h at 37°C. After incubation, the sample was concentrated, washed three times with 0.5 ml of 0.1% SDS, and reduced in volume to near dryness. The sample was then diluted up to 50 µl with sample buffer containing 0.5% 2-ME without SDS and alkylated with the addition of 1 µl of 4-vinylpyridine and run on SDS-11% PAGE.

In situ digestion of the protein in the polyacrylamide gel matrix was done by incubating the gel pieces with proteaseps Lys-C (Promega Biotec, Madison, WI) for 20 h at 37°C.

The resulting peptides were then subjected to narrow-bore, reverse-phase HPLC. The first step of peptide purification was made on a Vydac C4 (2.1 x 250-mm) column run in 0.1% TFA. Fractions of pure peptide were subjected to automated Edman sequencing on a protein sequencer (477A; Applied Biosystems, Inc., Foster City, CA) on line to the 120A Separation system.

cDNA Cloning. Degenerated sense and antiserous oligonucleotides, deduced from the amino acid sequences of two Lys-C peptides (Fig. 1), were used as primers to achieve PCR (25) on a pool of reversely transcribed RNA from human PBL activated with 10 ng/ml of PMA at various time points (30 min to 48 h). Amplification was carried out for 35 cycles (1-min denaturation at 95°C, 1-min annealing at 50°C, and 1.5-min elongation at 72°C) using an RNA PCR kit (Perkin Elmer Cetus, Norwalk, CT). Amplification of the 3' end of CD69 cDNA was achieved by PCR on reverse-transcribed RNA from PMA-activated PBL essentially as described (26), using the internal primer AIM 1 (5'-AGGAACCTGTCGACCAAATGG-3', nucleotides [nt] 521-540). To isolate the 5' end of CD69 cDNA, random-primed first-strand cDNA was synthesized from PMA-activated PBL mRNA by PCK on reverse-transcribed RNA from PMA-activated PBL essentially as described (26), using the internal primer AIM 3 (5'-TCCATGCTGCTGAACCTCTGTG-3', nt 616-636 of the [−] strand). To verify the nucleotide sequence of the CD69 open reading frame (ORF), two independent PCR were performed on PMA-activated PBL RNA using the primers AIM 6 (5'-GACCTCAACAAAGACTCTTAC-3', nt 12-31) and AIM 7 (5'-CTAAAATGAGACGTGTTTCT-3', nt 686-705 of the [−] strand) from the 5'- and 3'-untranslated regions. Amplification was carried out for 35 cycles (1-min denaturation at 95°C, 1-min annealing at 58°C, and 1.5-min elongation at 72°C). The amplification products of PCRs were purified from agarose gels by using the Gene Clean kit (Bio 101 Inc., La Jolla, CA) and cloned into pCR II plasmid (Invitrogen Corp., San Diego, CA).

DNA sequencing was performed by the dideoxy termination method (28) either by subcloning restriction fragments into Bluescript vectors or by direct oligonucleotide-primed DNA sequencing with internal primers when no convenient restriction sites were available.

Northern Blot Hybridization Analysis. Total RNA was isolated from human PBL, either untreated or treated with 10 ng/ml of PMA at various time points (0.5, 1, 3, 6, 12, 24, and 48 h) by the guanidine isothiocyanate method (29). A total of 10-20 µg of RNA of each sample was run on 1% formaldehyde-agarose gels and transferred onto nitrocellulose membranes. Hybridizations were performed by using the cloned 197-bp fragment, obtained by PCR.

1 Abbreviations used in this paper: nt, nucleotide; ORF, open reading frame.
with oligonucleotides 3.1+ and 4.2− (Fig. 1), as a 32P-labeled probe. To normalize by laser densitometry the CD69 mRNA expression, a 32P-labeled β-actin cDNA probe was used as control.

**Chromosome Mapping of the CD69 Gene.** Chromosomal localization of the CD69 gene by PCR was performed on DNA from interspecies hamster–human somatic cell hybrids (Biosomap™ Somatic Cell Hybrids PCRable™ DNAs; BIOS Corp., New Haven, CT) using the AIM 1 and 3 primers. The specificity of PCR products was confirmed by hybridization with a genomic CD69 probe, which included the sequence between the AIM 1 and 3 oligonucleotides.

The regional localization of the CD69 gene was assessed by fluorescence in situ hybridization with an EMBL3 phage containing a 15-kb genomic CD69 DNA. The λ-h CD69-1 phage, containing a 15-kb genomic insert, was isolated from a human genomic library constructed in the EMBL3 phage vector, as will be described elsewhere. The genomic clone was labeled by nick translation with digoxigenin-11-dUTP (Boehringer Mannheim, Mannheim, Germany) and diluted in hybridization buffer (50% formamide, 10% dextran sulphate, 2x SSC, and 50 mM phosphate, pH 7.0). After heat denaturation, 4 ng/μl of labeled probe was preannealed with a 500-fold excess of sonicated human placental DNA for 1 h at 37°C and hybridized overnight to denatured metaphase chromosomes from a normal male. Hybridization, washings, and detection with rhodamine-conjugated antibodies were performed as described (30). Chromosomes were counterstained with 75 ng/ml of 4'-6-diamino-2-phenylindole (DAPI) in antifade medium. After the fluorescent microscopy, GTG banding was performed as described (30).

**FACS® Analysis.** Fluorescence flow cytometry analysis was performed on a FACScan® cytofluorometer (Becton Dickinson & Co., Mountain View, CA). Cells were incubated at 4°C with 100 μl hybridoma culture supernatants, followed by washing and labeling with fluorescein isothiocyanate-labeled goat anti-mouse Ig (Pierce Chemical Co., Rockford, IL). Data were collected in a logarithmic scale, and percentage of positive cells was obtained by subtracting the background given by the mouse myeloma P3X63.

**Transfection of COS Cells, Indirect Immunofluorescence, and Immunoprecipitation.** To construct the CD69 expression vector (pAIM1-neo), a recombinant pCRII plasmid harboring the complete CD69 ORF and part of the 5' and 3' adjacent sequences (nt 12–705) was partially digested with BstXI and the resultant 700-bp fragment ligated to the plasmid pcDNA1-neo (Invitrogen Corp.) downstream of the cytomegalovirus promoter. The orientation of the insert was tested by restriction enzyme analysis.

For transient expression of CD69, monolayers of COS-7 cells were transfected with pAIM1-neo by the diethylaminoethyl-dextran method (31). Plasmid pcDNA1-neo was also included in the transfection as a control.

Transfected COS cells were grown on glass coverslips and cells were fixed in 3.7% formaldehyde in PBS for 10 min at room temperature. Cells were incubated with the primary antibody for 1 h at 37°C, rinsed in Tris-buffered saline, and stained with the appropriate dilution of the secondary antibody (FITC-labeled goat anti–mouse Ig; Pierce Chemical Co.). TPI/1 and TPI/55 mAbs were used as primary antibodies. Cells were observed using an Olympus photomicroscope (Nikon Inc., Instr. Group, Melville, NY).

Activated PBL, and transfected COS-7 cells harvested 72 h after transfection, were radiodinated in solution with chloroglycoluril (Iodogen; Pierce Chemical Co.). For immunoprecipitation, equal amounts of input radioactivity were mixed with 30 μl of different purified anti-CD69 mAb directly conjugated to Sepharose (2 mg/ml). Immunoprecipitates were processed as previously described (4) and samples were subjected to SDS-PAGE on 12% gels either under reducing or nonreducing conditions.

**Results**

**Isolation and Characterization of CD69 cDNA.** The CD69 glycoprotein was purified from PMA-activated human PBL by mAb affinity chromatography. Homogeneous CD69 protein was obtained as determined by SDS-PAGE followed by silver staining (Fig. 1 A). The purified protein was treated with N-glycanase, digested with Lys-C endopeptidase, and the resulting peptides were separated by reverse-phase HPLC and subjected to amino acid micro-sequencing. A total of 38 residues were determined from four independent peptides (Fig. 1 B). Degenerated sense and antisense oligonucleotides (Fig. 1 C) based on two Lys-C peptides (Fig. 1 B, underlined) were designed and used as primers to carry out PCR on reversely transcribed poly(A)+ RNA from a pool of PBL activated with PMA at different times (30 min to 24 h) (see below, Fig. 5 A). A DNA fragment of 197 bp was amplified using the oligonucleotides 3.1+ and 4.2−, whereas no amplification product was obtained with the oligonucleotides 4.1+ and 3.3−. The specificity of the 197-bp product was verified by a second PCR performed on the first PCR products, using the oligonucleotide 3.2+, which overlaps oligonucleotide 3.1+, and the oligonucleotide 4.2− (Fig. 1 C). The specific products of both PCRs were cloned and sequenced. The full-length cDNA was obtained by PCR after the rapid amplification of cDNA 5' and 3' ends (RACE) protocols (Fig. 1 D). The complete nucleotide sequence of the 1.7-kb CD69 cDNA and the amino acid sequence of the translation product is shown in Fig. 2.

To confirm the predicted amino acid sequence of the CD69 translation product, two additional independent PCRs were performed using primers from the 5'- and 3'-untranslated sequences adjacent to the ORF. No polymerase-induced mutations were observed on these cloned PCR products. The ORF extended from nt 82 to 678, and contained the amino acid sequences of the four different Lys-C peptides. ORF was preceded by a 5'-untranslated region of 81 bp and followed by a 3'-untranslated region of 1,023 bp, which contained three poly(A) and multiple rapid degradation signals (Fig. 2).

**Expression of CD69 Antigen in COS Cells.** To confirm that the cDNA isolated was encoding CD69 antigen, COS-7 cells were transfected with the CD69 ORF, which was placed under the control of the cytomegalovirus promoter. Transfected cells reacted with several anti-CD69 mAbs as shown by immunofluorescence (Fig. 3 A). Furthermore, immunoprecipitation with mAb directed against extracellular and intracellular epitopes of the CD69 antigen (8) from 125I externally labeled transfected COS-7 cells yielded two bands under reducing conditions, which corresponded to the 27- and 33-kD bands of the native CD69 precipitated from activated PBL (Fig. 3 B). Under nonreducing conditions, immunoprecipitation with anti-CD69 mAb yielded a single band of 60 kD, which is the expected molecular mass of the disulfide-linked CD69 homodimer (Fig. 3 B). These results demonstrate that
the cDNA-encoded CD69 protein possesses identical properties as native CD69 antigen.

**Predicted Amino Acid Sequence of the CD69 Translation Product.** The deduced amino acid sequence of the CD69 ORF corresponded to a polypeptide of 199 residues with a predicted molecular weight of 22,545, which is in agreement with the previously reported molecular weight of deglycosylated CD69 protein (22,000–24,000) (6, 8). This polypeptide was devoid of NH₂-terminal hydrophobic signal peptide but contained a transmembrane domain of 26 amino acids as predicted by hidrophobicity analysis (32). These features on the primary structure of CD69 indicated that it is a type II integral membrane protein and is therefore composed of a NH₂-terminal cytoplasmic domain of 38 residues, a single transmembrane region of 26 residues, and an extracellular COOH-terminal domain of 135 amino acids.

A putative site was found for N-linked glycosylation in the extracellular domain of CD69 (Fig. 2). The existence of this N-linked glycosylation site is in agreement with previous results demonstrating, by both glycosidase and tunicamycin treatments, the presence of N-linked glycosylation in the CD69 protein (6, 8). Several potential phosphorylation sites for serine/threonine kinases, PKC, and casein kinase II were found within the cytoplasmic tail (Fig. 2), in accordance with the constitutive Ser/Thr phosphorylation of CD69 in both mature thymocytes and activated T lymphocytes (6, 14, 33).

**CD69 Is a Member of the C-Type Animal Lectin Superfamily.** Comparison of the predicted amino acid sequence with the SWISSPROT and EMBL databases using the search algorithm FASTA (34) indicated that CD69 has homology with proteins of the animal C-type lectin superfamily, which also possess the unusual type II membrane orientation (Fig. 4). Most markedly, computer-aided comparisons using the BESTFIT program revealed that CD69 has strong amino acid sequence similarity ranging from 44 to 48% with the human NKG2 (35), and the rat and mouse NKR-P1 protein families (36, 37). It was found that CD69 protein is also homologous to the human and mouse low affinity IgE receptor (CD23) (38–40), the hepatic asialoglycoprotein receptor (41), and the mouse T cell antigen Ly49 (42, 43). The highest sequence similarity was confined mainly to the C-type lectin domain, which covers a stretch of 116 amino acids of the CD69 polypeptide, the most striking feature being the presence of 12 invariant residues (Fig. 4). Particularly important is the...
and then the total RNA was subjected to Northern blot analysis of RNA from untreated and PMA-treated PBL using a specific CD69 cDNA probe showed a PMA-inducible RNA species of 1.7 kb, in agreement with the size of the isolated amplification product of 1.1 kb was obtained only in those hybrids containing chromosome 12 (lane 4). The presence of CD69 mRNA was detected by hybridization of RNA from interspecies hamster-human somatic cell hybrids (Fig. 6 A), an amplification product of 1.1 kb was obtained only in those hybrids containing chromosome 12 (lane 4). The presence

The early expression of CD69 protein upon T cell activation together with the presence of rapid degradation signals at the 3' untranslated region of the CD69 cDNA led us to analyze the induction kinetics of the CD69 mRNA. Therefore, PBL were stimulated with PMA at various time points, and then the total RNA was subjected to Northern blot analysis with a CD69 cDNA probe (Fig. 5 B). In parallel, the surface expression of CD69 antigen was assessed by flow cytometry (Fig. 5 C). CD69 mRNA showed a transient increase after exposure of cells to PMA. It became detectable by 30 min to 1 h, with maximal expression by 6 h, reaching a 50-fold increase, and declined thereafter to undetectable levels (Fig. 5 B). The surface expression of CD69 antigen displayed a slower kinetics compared with that of the mRNA induction. It reached a peak by 12 h of PMA treatment, declined by 24 h, and then the induced level persisted for at least 48 h (Fig. 5 C). These results indicated that the level of CD69 mRNA regulates CD69 protein expression. Similarly, Northern blot analysis performed on RNA from different cell lines, which were either unstimulated or stimulated with PMA for 6 h, showed that the tissue-specific distribution of CD69 antigen is regulated at transcriptional level (data not shown).

Chromosomal Assignment of the CD69 Gene. The CD69 gene was located on chromosome 12 by PCR analysis of DNA from interspecies hamster–human somatic cell hybrids (Fig. 6, and data not shown). As observed in Fig. 6 A, an amplification product of 1.1 kb was obtained only in those hybrids containing chromosome 12 (lane 4). The presence

conserved placement of six of the Cys residues (Fig. 4), which appear to be involved in disulfide bonds (41, 44). Although there are no long continuous stretches of invariant residues, almost all of the essential residues conforming the C-type carbohydrate recognition domain (41) are present at approximately the same spacing. CD69 also showed certain degree of similarity with the transmembrane and cytoplasmic regions of other C-type lectin cell surface receptors expressed by leukocytes, such as the NKG2 and NKR-P1 members.

CD69 mRNA Expression. The cell surface expression of CD69 is almost exclusively restricted to leukocytes and is transiently induced upon treatment of lymphocytes with several mitogenic reagents such as phorbol esters (4). Northern blot analysis of RNA from untreated and PMA-treated PBL using a specific CD69 cDNA probe showed a PMA-inducible RNA species of 1.7 kb, in agreement with the size of the isolated cDNA (Fig. 5 A).

The early expression of CD69 protein upon T cell activation together with the presence of rapid degradation signals at the 3' untranslated region of the CD69 cDNA led us to analyze the induction kinetics of the CD69 mRNA. Therefore, PBL were stimulated with PMA at various time points, and then the total RNA was subjected to Northern blot analysis with a CD69 cDNA probe (Fig. 5 B). In parallel, the surface expression of CD69 antigen was assessed by flow cytometry (Fig. 5 C). CD69 mRNA showed a transient increase after exposure of cells to PMA. It became detectable by 30 min to 1 h, with maximal expression by 6 h, reaching a 50-fold increase, and declined thereafter to undetectable levels (Fig. 5 B). The surface expression of CD69 antigen displayed a slower kinetics compared with that of the mRNA induction. It reached a peak by 12 h of PMA treatment, declined by 24 h, and then the induced level persisted for at least 48 h (Fig. 5 C). These results indicated that the level of CD69 mRNA regulates CD69 protein expression. Similarly, Northern blot analysis performed on RNA from different cell lines, which were either unstimulated or stimulated with PMA for 6 h, showed that the tissue-specific distribution of CD69 antigen is regulated at transcriptional level (data not shown).

Chromosomal Assignment of the CD69 Gene. The CD69 gene was located on chromosome 12 by PCR analysis of DNA from interspecies hamster–human somatic cell hybrids (Fig. 6, and data not shown). As observed in Fig. 6 A, an amplification product of 1.1 kb was obtained only in those hybrids containing chromosome 12 (lane 4). The presence

Figure 2. CD69 cDNA nucleotide sequence and predicted amino acid sequence. The transmembrane domain is double underlined, and potential polyadenylation signals are single underlined. Potential rapid degradation signals are in boxes. Putative N-linked glycosylation sites are indicated by asterisks and phosphorylation sites are PKC and casein kinase II (CK2). These sequence data have been submitted to the EMBL Data Library under accession number Z22576.
Figure 3. Transient expression of cDNA-encoded CD69 in COS-7 cells. (A) Immunofluorescence staining of CD69-transfected cells with anti-CD69 TP1/8 and TP1/55 mAbs. The monoclonal Ig from P3X63 myeloma was included as negative control. (B) Immunoprecipitation analysis of CD69 from transfected COS cells. Lysates from 35S-labeled transfected cells with pcDNA1-Neo (vector without an insert) (lanes 1-3), transfected with pAIMI-Neo (containing the CD69 ORF) (lanes 4-6), and PMA-activated PBL (lanes 7-9) were precipitated with the following antibodies: P3X63 as negative control (lanes 1, 4, and 7), the anti-CD69 TP1/8 (lanes 2, 5, and 8), and CH/2 mAbs (lanes 3, 6, and 9) specific for extracellular and intracellular epitopes, respectively. The samples were analyzed by SDS-12% PAGE under reducing conditions. Precipitates with the anti-CD69 TP1/8 mAb from PMA-activated PBL (lane 10) and from pAIMI-Neo-transfected cells (lane 11) were also analyzed under nonreducing conditions.

Figure 4. Sequence alignment of the lectin-like domains of CD69 protein and several other members of the supergene family. The amino acid positions within each sequence are shown. Filled circles indicate positions where the residue is highly conserved. The six invariant Cys residues are enclosed within black boxes. Identities between CD69 and other C-type lectins are shaded; (h) human, and (m) mouse.
Figure 5. Analysis of human CD69 mRNA. (A) Northern blot analysis of RNA from untreated (lane -) and PMA-treated PBL (lane +) with a 32P-labeled CD69-cDNA fragment spanning nt 482-678. Positions of the ribosomal 28S and 18S RNA are indicated on the left. (B) Induction kinetics of CD69 mRNA. PBL were stimulated with PMA (10 ng/ml) at various time points (30 min, and 1, 3, 6, 12, 24, and 48 h), and the total RNA of each sample was prepared and subjected to Northern blot analysis with the same CD69 cDNA probe described above. A β-actin cDNA probe was used as a control for loading amounts. (C) Diagrammatic representation of the induction kinetics of CD69 mRNA and protein. Laser densitometry giving corrected scanning units of the CD69 mRNA expression normalized to the β-actin control gene is represented by filled circles. Surface expression of CD69 protein analyzed by flow cytometry is represented by open squares. (MFI), mean fluorescence intensity.

Discussion

This study describes the cloning and sequencing of the cDNA encoding the human early lymphocyte activation antigen CD69. The molecular cloning of CD69 antigen was achieved by a combined strategy that included partial protein sequencing and PCR techniques. Confirmation that the cloned cDNA indeed represents CD69 is based on several lines of evidence. (a) The predicted amino acid sequence encoded by the ORF is a protein with a molecular weight of 22,545, which is similar to the reported molecular weight (22,000-24,000) of the deglycosylated native CD69 protein (6, 8); (b) the four peptide sequences obtained from the CD69-purified protein are found in the translated sequence of the isolated gene; and (c) transfection of COS cells with the cloned CD69 cDNA shows that a disulfide-linked homodimer of the expected molecular weight under both reducing and non-reducing SDS-PAGE conditions can be precipitated by several anti-CD69 mAbs that are directed against extracellular and intracellular epitopes of the molecule (8).

The ORF of CD69 cDNA predicts a 199-amino acid polypeptide with a type II transmembrane topology. The extracellular COOH-terminal domain possesses an available site for N-linked glycosylation as proposed for the native protein (6, 8). Previous studies of cell protease treatments revealed the presence of a CD69 pronase-resistant peptide of 16,000 Mr that lost the external epitopes, suggesting that the native protein could be predominantly an intracellular protein (8). However, it is now evident that CD69 indeed possesses a large protease-resistant fragment in the extracellular region of the protein. This is in accordance with the observations that the purified glycosylated native protein was refractory to protease fragmentation, and that most of the currently used proteases failed to cleave the deglycosylated protein without previous SDS denaturation (8). Taken together, these findings show that the majority of the antigenic sites recognized by different CD69 antibodies, including those with agonistic properties, would be located in the terminal fragment of the external domain, likely into the lectin domain.

The regulation of the expression of CD69 in PBL appears to be of remarkable interest. Like other immediate early genes (45, 46), the CD69 gene displays a rapid and transient expression, followed by a rapid decay and degradation at the RNA level. The presence of reiterate rapid degradation signals (47) at the 3' end of CD69 mRNA may explain its rapid turnover. This tight regulation ensures the transient activation of this gene and contributes to prevent the uncontrolled expression of the CD69 receptor implicated in lymphocyte proliferation. The pattern of CD69 gene expression closely resembles that of proto-oncogenes and most cytokines in lymphocytes, and it is clearly distinct from that of other lymphocyte activation molecules such as the IL-2 and transferrin receptors, which exhibit a slower kinetics of both RNA induction and degradation (1, 48). However, the expression of the CD69 protein on lymphocyte cell surface persisted for longer periods of time. This may be attributed to the high stability of the CD69 glycoprotein, and its refractoriness to proteolytic mechanisms as discussed above. Whatever the mechanisms regulating the expression of the CD69 gene are, they remain unknown and deserve further investigation.

Comparison of CD69 cDNA with known sequences indicates that the extracellular region of CD69 is characterized by the presence of a C-type animal lectin domain with similar membrane orientation and protein sequence as those found in members of this lectin family. Hence, CD69 is related to a growing family of type II transmembrane receptors, which includes the gene families coding for human NKG2 (35), rat...
NKR-P1 (36), and mouse NKR-P1 (37, 49), which show preferential expression on LAK and NK cells. Other type II lectin cell surface receptors with structural similarities to CD69 are the mouse Ly 49 (42, 43) expressed by activated T cells, the CD23 low affinity Fce receptor, present on activated B cells and monocytes (38–40, 50), and the hepatic asialoglycoprotein receptors implicated in the clearance of plasma glycoproteins (41). Interestingly, the intracellular domain of CD69 maintains a certain degree of sequence homology only with members of the lectin superfamily expressed by leukocytes, but not with lectin receptors found in hepatocytes.

Our studies by PCR analysis on somatic cell hybrid DNA demonstrate that the human CD69 gene is located on chromosome 12, in accordance with previous serological analysis of human–mouse somatic cell hybrids (51). In addition, we have regionally mapped the CD69 gene to the distal region of the short arm of chromosome 12, bands p13-p12. Interestingly, the genes coding for Ly 49 and NK1.1 antigens are closely linked within the distal portion of mouse chromosome 6, which is the homologous region with human chromosome 12p (52, 53). The possibility of a gene cluster encoding this family of C-lectin receptors expressed by activated T lymphocytes and NK cells raises important questions in terms of both the regulation of gene expression and their function in leukocyte activation.

The CD69 protein shares structural and functional features with NK-specific receptors encoded by human NK2 and rat and mouse NKR-P1 (53). All are disulfide-linked dimers with a similar molecular size whose expression is either induced or enhanced during activation of T lymphocytes and NK cells. Although differentially expressed among leukocytes, all these molecules act as triggering structures. The activating effect of antibodies specific for the mouse and human CD69 antigen in stimulating redirected target cell lysis by IL-2-activated NK cells (22, 23) is similar to that described with
antibodies specific for other members of the family such as mouse NK1.1 and rat NKR-P1 antigens (22, 54). Furthermore, CD69 antibodies are capable of inducing intracellular signals, including mobilization of intracellular calcium and T cell proliferation in conjunction with suboptimal doses of phorbol esters (4, 19). Similarly, NKR-P1 also functions as a receptor for the Fc portion of IgE and, additionally, its interaction with the B cell antigen CD21 has recently been reported (57). The region involved in the interaction with IgE has been demonstrated to correspond almost exactly to the domain homologous with animal lectins (58). The integrity of the invariant cysteines is absolutely required for IgE binding (58).

The expression of a C-type lectin domain by the members of this superfamily of transmembrane receptors suggests their possible interaction with carbohydrates in a calcium-dependent manner. Evidence for such a role has been described for the CD23 member of the family (59). In addition, studies supporting the possibility that carbohydrate structures are involved in recognition events mediated by NK cells have been reported (60). However, the identification of such putative carbohydrate ligands is required to elucidate the functional role of the lectin domain of CD69 and the other members of this family of signal transmembrane receptors.

It is important to remark that although CD69 is absent on circulating PBL, it is expressed at remarkably high levels in the majority of T cells in the inflammatory infiltrates of several human diseases. Thus, CD69 expression has been detected in T lymphocytes of synovial membrane and synovial fluid from rheumatoid arthritis patients (12), as well as on CD8+ T cells in infiltrates of virus-induced chronic inflammatory liver diseases (11). In addition, CD69 is also expressed by certain CD4+ T cells in the germinal centers of normal lymph nodes and by a small subpopulation of medullary thymocytes (13, 14). Therefore, it could be hypothesized that CD69 functions as an immediate early receptor that would be required for tissue positioning and localization, and/or for migration toward sites of inflammation. Conceivably, the expression of a C-type lectin domain externally exposed on CD69 may enable its interaction with carbohydrate moieties, allowing T cell migration across the endothelial cell layer and different tissue components. The molecular characterization of the CD69 protein and its adscription to this superfamily of C-lectin signaling molecules provide new insights regarding the possible functional role of these cell surface transmembrane receptors.

We thank Drs. A. L. Corbi, J. M. Redondo, M. A. Vega, R. González-Amaro, M. O. de Landázuri, and M. López-Botet for critical reading of the manuscript. We acknowledge the contribution of Dr. A. L. Corbi in an early step of this work, Dr. M. A. Vega for his helpful interpretation of amino acid sequences, and A. Rodríguez for his help in transfection and sequencing. We are also indebted to the Spanish EMBNet node for the computing and nucleotide data base facilities. The superb typing assistance of I. Moreno Montes is also acknowledged.

This work was supported by grants from INSALUD (FIS 91/0259 and PB92-0318), and by fellowships from Spanish Ministry of Education and Science (M. López-Cabrera), and Comunidad Autónoma Madrid (A. G. Santis and P. Sánchez-Mateos).

Address correspondence to F. Sánchez-Madrid, Servicio de Inmunología, Hospital de la Princesa, c/Diego de León, 62, 28006 Madrid, Spain.

Received for publication 24 March 1993.

References

1. Ullman, K., J.P. Northrop, C.L. Verweij, and G.R. Crabtree. 1990. Transmission of signals from T lymphocyte antigen receptor to the genes responsible for cell proliferation and immune function. Annu. Rev. Immunol. 8:421.
2. Crabtree, G.R. 1989. Contingent genetic regulatory events in T lymphocyte activation. Science (Wash. DC). 243:355.
3. Schwarting, R., G. Niedobitek, and H. Stein. 1989. Cluster report: CD69. In Leucocyte Typing IV. White Cell Differentiation Antigens. W. Knapp, B. Doeren, W.R. Gilks, E.P. Rieber, R.E. Schmidt, H. Stein, and A. Von der Borne, editors. Oxford University Press, Oxford. 428-432.
4. Cebrián, M., E. Yagüe, M. Rincón, M. López-Botet, M.O. de Landázuri, and F. Sánchez-Madrid. 1988. Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes. J. Exp. Med. 168:1621.
5. Hara, T., L.K.L. Jung, J.M. Bjorndahl, and S.M. Fu. 1986. Human T cell activation. III. Rapid induction of a phosphorylated 28 kD/32 kD disulfide-linked early activation antigen (EA 1) by 12-O-tetradecanoyl phorbol-13-acetate,
mitogens, and antigens. J. Exp. Med. 164:1988.
6. Lanier, L.L., D.W. Buck, L. Rhodes, A. Ding, E. Evans, C. Barney, and J.H. Phillips. 1988. Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-2 antigen. J. Exp. Med. 167:1572.
7. Cosulich, E., Rubartelli, A. Risso, F. Cozzolino, and A. Bargellesi. 1987. Functional characterization of an antigen involved in an early step of T-cell activation. Proc. Natl. Acad. Sci. USA. 84:4205.
8. Sánchez-Mateos, P., and F. Sánchez-Madrid. 1991. Structure-function relationship and immunological mapping of external and intracellular antigenic sites on the lymphocyte activation inducer molecule, AIM/CD69. Eur. J. Immunol. 21:2317.
9. Cebrián, M., J.M. Redondo, A. López-Rivas, G. Rodriguez-Tarduchy, M.O. de Landázuri, and F. Sánchez-Madrid. 1989. Expression and function of AIM, an activation inducer molecule of human lymphocytes, is dependent on the activation of protein kinase C. Eur. J. Immunol. 19:809.
10. Bjordahl, H.M., S. Nakamura, T. Hara, L.K.L. Jung, and S.M. Fu. 1988. The 28/32 kDa activation antigen EA1. Further characterization and signal requirements for its expression. J. Immunol. 141:4094.
11. García-Monzón, C., R. Moreno-Otero, J.M. Pájares, A. García-Sánchez, M. López-Botet, M.O. de Landázuri, and F. Sánchez-Madrid. 1990. Expression of a novel T cell activation antigen (AIM) on CD8+ T lymphocytes in the inflammatory infiltrate in virus-related chronic active hepatitis. Gastroenterology. 98:126.
12. Lafuente, A., R. García-Vicuña, A. Humbria, P.A. Postigo, A.L. Corbí, M.O. de Landázuri, and F. Sánchez-Madrid. 1991. Up-regulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J. Clin. Invest. 88:346.
13. Sánchez-Mateos, P., M. Cebrián, A. Acevedo, M. López-Botet, M.O. de Landázuri, and F. Sánchez-Madrid. 1989. Expression of a gp33/27,000 m.w. activation inducer molecule (AIM) on human lymphoid tissues. Induction of cell proliferation on thymocytes and B lymphocytes by anti-AIM antibodies. Immunology. 68:72.
14. Testi, R., J.H. Phillips, and L.L. Lanier. 1988. Constitutive expression of phosphorylated activation antigen (Leu 23) by CD3+ human thymocytes. J. Immunol. 141:2557.
15. Jung, L.K.L., B.F. Haynes, S. Nakamura, S. Pahwa, and S.M. Fu. 1990. Expression of early activation antigen (CD69) during human thymic development. Clin. Exp. Immunol. 81:466.
16. Testi, R., F. Pulcinelli, L. Frati, P.P. Gazzaniga, and A. Santoni. 1990. CD69 is expressed on platelets and mediates platelet activation and aggregation. J. Exp. Med. 172:701.
17. Bieber, T., A. Rieger, G. Stingl, E. Sander, P. Wanek, and I. Strobel. 1992. CD69, an early activation antigen on lymphocytes, is constitutively expressed by human epidermal Langerhans cells. J. Invest. Dermatol. 98:771.
18. Nakamura, S., S.J. Sung, J.M. Bjordahl, and S.M. Fu. 1989. Human T cell activation. IV. T cell activation and proliferation via the early activation antigen Ea-1. J. Exp. Med. 169:677.
19. Testi, R., J.H. Phillips, and L.L. Lanier. 1989. T cell activation via Leu-23 (CD69). J. Immunol. 143:1123.
20. Santis, A.G., M.R. Campanero, J.L. Alonso, A. Tugores, M.A. Alonso, E. Yagüe, J.P. Pivel, and F. Sánchez-Madrid. 1992. TNFα production induced in T lymphocytes through the AIM/CD69 activation pathway. Eur. J. Immunol. 22:1253.
21. Tugores, A., M.A. Alonso, F. Sánchez-Madrid, and M.O. de Landázuri. 1992. Human T cell activation through the activation-inducer molecule/CD69 enhances the activity of transcription factor AP-1. J. Immunol. 148:2300.
22. Karlhofer, F.M., and W.M. Yokoyama. 1991. Stimulation of murine natural killer (NK) cells by a monoclonal antibody specific for the NK1.1 antigen: IL-2-activated NK cells possess additional specific stimulation pathways. J. Immunol. 146:3652.
23. Moretta, A., A. Poggio, D. Pende, G. Trippodi, A.M. Oreno, N. Pella, R. Augugliaro, C. Bottino, E. Ciccone, and L. Moretta. 1991. CD69-mediated pathway of lymphocyte activation: anti-CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytotytic T lymphocytes expressing T cell receptor α/β. J. Exp. Med. 174:1393.
24. Risso, A., D. Smilovich, M.C. Capra, I. Baldissarro, G. Yan, A. Bargellesi, and M.E. Cosulich. 1991. CD69 in resting and activated T lymphocytes. Its association with a GTP binding protein and biochemical requirements for its expression. J. Immunol. 146:4105.
25. Saiki, R.K., S. Scharf, F. Faloona, K.B. Mullis, G.T. Horn, H.A. Erlich, and N. Arnheim. 1985. Enzymatic amplification of β-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science (Wash. DC). 230:1350.
26. Frohman, M.A., M.K. Dush, and G.R. Martin. 1988. Rapid production of full-length DNA from rare transcripts: amplification using a single gene specific oligonucleotide primer. Proc. Natl. Acad. Sci. USA. 85:8998.
27. Harvey, R.J., and M.G. Darlington. 1991. Random-primed cDNA synthesis facilitates the isolation of multiple 5′-cDNA ends by RACE. Nucl. Acids Res. 19:4002.
28. Sanger, F., S. Nicklen, and A.R. Coulson. 1977. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. USA. 74:5463.
29. Chirgwin, J.M., A.E. Przybyla, E.C. Niemi, W.M. Yokoyama, and W.E. Rutter. 1979. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry. 18:5294.
30. Fernández-Ruiz, E., F. Parodo-Manuel, M.A. Rubio, A.L. Corbi, S. Rodríguez de Córdoba, and F. Sánchez-Madrid. 1992. Mapping of the human VLA-α4 gene to chromosome 2q31-q32. Eur. J. Immunol. 22:587.
31. Seed, B., A. Aruffo. 1987. Molecular cloning of the CD2 antigen, the T-cell erythocyte receptor, by a rapid immunoselection procedure. Proc. Natl. Acad. Sci. USA. 74:3365.
32. Kyte, J., and R.F. Doolittle. 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157:105.
33. Risso, A., M.E. Cosulich, A. Rubartelli, M.R. Maizza, and A. Bargellesi. 1989. MLR3 molecule is an activation antigen shared by human B, T lymphocytes and T cell precursors. Eur. J. Immunol. 19:323.
34. Pearson, W.R., and D.J. Lipman. 1988. Improved tools for biological sequence comparison. Proc. Natl. Acad. Sci. USA. 85:2444.
35. Houchins, J.P., T. Yabe, C. McSherry, and F.H. Bach. 1991. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J. Exp. Med. 173:1017.
36. Giorda, K., W.A. Kudert, C. Vavassori, W.H. Chambers, J.C. Hiserodt, and M. Trucco. 1990. NKR-P1, a signal transduction molecule on NK cells. Science (Wash. DC). 249:1298.
37. Ryan, J.C., J. Turek, E.C. Niemi, W.M. Yokoyama, and W.E. Seaman. 1992. Molecular cloning of the NK 1.1 antigen, a member of the NKR-P1 family of natural killer cell activation molecules. J. Immunol. 149:1631.
38. Bettler, B., H. Hofstetter, M. Rado, W.M. Yokoyama, F. Kilch-
herr, and D.H. Conrad. 1989. Molecular structure and expression of the murine lymphocyte low affinity receptor for IgE (FeRIII). Proc. Natl. Acad. Sci. USA. 86:7566.

39. Kikutani, H., S. Inui, R. Sato, E.L. Barsumian, H. Owaki, K. Yamasaki, T. Kaisho, N. Uchibayashi, R.P. Hardy, T. Hirano, S. Tsumasawa, F. Sakiyama, M. Suemura, and T. Kishimoto. 1986. Molecular structure of human lymphocyte receptor for immunoglobulin E. Cell. 47:657.

40. Ikuta, K., M. Takami, C.W. Kim, T. Honjo, T. Miyoshi, J. Tagaya, T. Kawabe, and J. Yodoi. 1987. Human lymphocyte Fc receptor for IgE: sequence homology of its cloned cDNA with animal lectins. Proc. Natl. Acad. Sci. USA. 84:819.

41. Drickamer, K. 1988. Two distinct classes of carbohydrate-recognition domains in animal lectins. J. Biol. Chem. 263:9557.

42. Yokoyama, W.M., L.B. Jacobs, O. Kanagawa, E.M. Shevach, and D.I. Cohen. 1989. A murine T lymphocyte antigen belongs to a supergene family of type II integral membrane proteins. J. Immunol. 142:1727.

43. Chan, P.-Y., and F. Takei. 1989. Molecular cloning and characterization of a novel murine T cell surface antigen. YE1/48. J. Immunol. 142:1727.

44. Takahashi, H., H. Komano, N. Kawaguchi, N. Kitamura, S. Nakanishi, and S. Natori. 1985. Cloning and sequencing of cDNA of Sarcophaga peregrina humoral lectin induced by injury of the body wall. J. Biol. Chem. 260:12228.

45. Caput, D., B. Beutler, K. Hartog, R. Thayer, S. Brown-Shimer, and A. Cerami. 1986. Identification of a common nucleotide sequence in the 3'-untranslated region of mRNA molecules specifying inflammatory mediators. Proc. Natl. Acad. Sci. USA. 83:1670.

46. Gaugitch, H.W., E.E. Prieschl, F. Kalthoff, N.E. Huber, and T. Baumrucker. 1992. A novel transiently expressed, integral membrane protein linked to cell activation. J. Biol. Chem. 267:11267.

47. Shaw, G., and R. Kamen. 1986. A conserved AU sequence from 3'-untranslated region of GM-CSF mediates selective mRNA degradation. Cell. 46:659.

48. Reed, J.C., J.D. Alpers, P.C. Nowell, and R.G. Hoover. 1986. Sequential expression of proto-oncogenes during lectin-stimulated mitogenesis of normal human lymphocytes. Proc. Natl. Acad. Sci. USA. 83:3982.

49. Giorda, R., and M. Trucco. 1991. Mouse NKR-P1. A family of genes selectively co-expressed in adherent lymphokine-activated killer cells. J. Immunol. 147:1701.

50. Ludin, C., H. Hofstetter, M. Sarfati, C.A. Levy, U. Suter, D. Alaimo, E. Kilcherr, H. Frost, and G. Deleppesee. 1987. Cloning and expression of the cDNA coding for a human lymphocyte IgE receptor. EMBO (Eur. Mol. Biol. Organ.) J. 6:109.

51. Cambiaggi, C., M.T. Scopoli, T. Cestari, F. Gerosa, G. Carra, G. Tridente, and R.S. Accolla. 1992. Constitutive expression of CD69 in interspecies T-cell hybrids and locus assignment to human chromosome 12. Immunogenet. 36:117.

52. Yokoyama, W.M., J.C. Ryan, J.J. Hunter, H.R.C. Smith, M. Stark, and W.E. Seaman. 1991. cDNA cloning of mouse NKR-P1 and genetic linkage with Ly-49. Identification of a natural killer cell gene complex on mouse chromosome 6. J. Immunol. 147:3229.

53. Yokoyama, W.M. 1993. Recognition of structures on natural killer cells. Curr. Opin. Immunol. 5:67.

54. Chambers, W.H., N.L. Vujanovic, A.B. DeLeo, M.W. Olzowy, R.B. Herberman, and J.C. Hiserodt. 1989. Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells. J. Exp Med. 169:1373.

55. Ryan, J.C., E.C. Niemi, R.D. Goldfien, J.C. Hiserodt, and W.E. Seaman. 1991. NKR-P1, an activating molecule on rat natural killer cells, stimulates phosphoinositide turnover and rise in intracellular calcium. J. Immunol. 147:3244.

56. Conrad, D.H. 1990. FcRII/CD23: the low affinity receptor for IgE. Annu. Rev. Immunol. 8:623.

57. Aubry, J.-P., S. Pochon, P. Graber, K.V. Jansen, and J.-Y. Bonnefoy. 1992. CD21 is a ligand for CD23 and regulates IgE production. Nature (Lond.). 358:505.

58. Beckler, B., R. Maier, D. Rüegg, and H. Hofstetter. 1989. Binding site for IgE of the human lymphocyte low affinity Fc receptor (FcRII/CD23) is confined to the domain homologous with animal lectins. Proc. Natl. Acad. Sci. USA. 86:7118.

59. Chretien, I., B. Helm, P. Marsh, E. Padlan, J. Wijdenes, and J. Banchereau. 1988. A monoclonal anti-IgE antibody against an epitope (aminoacids 367-376) in the CH3 domain inhibits IgE binding to the low affinity IgE receptor (CD23). J. Immunol. 141:3128.

60. McCoy, J.P., and W.H. Chambers. 1991. Carbohydrates in the functions of natural killer cells. Glycobiology. 1:321.